MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

According to our recent payer coverage analysis for type 2 Diabetes (DPP4 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for type 2 Diabetes (DPP4 and Combo) treatments shows that under the pharmacy benefit, almost 40% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In December 2019, Lexicon Pharmaceuticals, Inc. reported topline data from their Phase III SOTA-EMPA study for Zynquista (sotagliflozin) in type 2 diabetes, according to the company.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

professional-psychologist-doctor-consult-in-psychotherapy-session
September 23

MMIT Reality Check on Schizophrenia (September 2022)

Read More
woman-suffering-from-bad-headache-or-migraine-appointment-with-doctor-in-office-room
September 16

MMIT Reality Check on Acute Migraine (September 2022)

Read More
doctor-with-senior-woman-infusion
September 9

MMIT Reality Check on Breast Cancer HR+/HER2- (September 2022)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today